seekingalpha.com · 25 jun

Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon

Alumis receives a renewed Buy rating, driven by upcoming data catalysts for lead candidate envudeucitinib in psoriasis and SLE. Phase 3 data for envudeucitinib showed strong efficacy and safety, though not outright superiority versus competitors, and twice-daily dosing is a minor drawback. Upcoming 2026 catalysts include long-term psoriasis data, NDA submission, and pivotal SLE data, all critical for valuation and acquisition potential.

fool.com · 24 may

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.

fool.com · 17 may

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.

fool.com · 15 may

Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back

Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.

globenewswire.com · 14 may

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –

fool.com · 10 may

Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.